Role of intermediary biomarkers in determining the anticancer efficacy of marine compounds

Medicinal Chemistry Research

Volumn 13, Issue 6-7, 2004, Pages 553-562

  Arif, Jamal M ^a   Kunhi, Mohammed ^a   Siddiqui, Yunus M ^a   El Sayed, Khalid A ^b   Orabi, Khaled Y ^c   Al Hazzani, Amal ^a   Al Ahdal, Mohammed N ^a   Al Khodairy, Fahad M ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^c KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE; BIOLOGICAL MARKER; MANZAMINE A; PROTEIN P53; SARCOPHINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CANCER GROWTH; CELL STRAIN MCF 7; CONFERENCE PAPER; DNA ADDUCT; DNA REPAIR; DRUG EFFICACY; GENOTOXICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

EID: 20344368337     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00044-004-0054-2     Document Type: Conference Paper

References (32)

1. Garcia-Fernandez LF, Reyes F, Sanchez-Puelles JM. Pharmaceut. News 2002; 9: 495-501.
2. Arif JM, Al-Hazzani AA, Kunhi M, Al-Khodairy FM. J. Biomed. Biotechnol. 2004; (in press).
3. Mayer AM, Lehmann VKB. Anticancer Res. 2001; 21: 2489-2500.
4. Haefher B. Drugs from the deep: marine natural products as drug candidates. Drugs Discov. Today 2003; 8: 536-543.
5. Anzai N, Taniyama T, Nakandakari N, Sugiyama C, Negishi T, Hayatsu H, Negishi K. Jpn. J. Cancer Res. 2001; 92: 848-853.
6. Sugiyama C, Nakandakari N, Hayatsu H & Arimoto-Kobayashi S. Biol. Pharm. Bull. 2002; 25: 520-522.
7. Ang KK, Holmes MJ & Kara UA. Parasitol. Res. 2001; 87:715-721.
8. Ichiba T, Corgiat JM, Scheuer PJ, Kelly-Borges M. J. Nat. Prod. 1994; 57:168-170.
9. Edrada RA, Proksch P, Wray V, Witte L, Muller WE, Van Soest RW. J. Nat. Prod. 1996; 59:1056-1060.
10. El Sayed KA, Hamann MT, Waddling CA, Jensen C, Lee SK, Dunstan CA, Pezzuto JM. J. Org. Chem. 1998; 63: 7449-7455.
11. Matsumoto SS, Sidford MH, Holden JA, Barrows LR, Copp BR. Tetrahedron Lett. 2000; 41: 1667-1670.
12. Aune GJ, Furuta T, Pommier Y. Anticancer Drugs 2002; 13: 545-555.
13. Sakai R, Higa T, Jefford CW, Bernardinelli G. J. Am. Chem. Soc. 1986; 108: 6404-6405.
14. El Sayed KA, Kelly M, Kara UAK, Ang KKH, Katsuyama ID, Dunbar C, Khan AA, Hamann MT. J. Am. Chem. Soc. 2001; 123:1804-1808.
15. Bernstein J, Shmeuli U, Zadock E, Kashman Y, Neeman I. Tetrahedron 1974; 30:2817-2824.
16. Gupta RC. In: Technologies for Detection of DNA Damage and Mutations, Pfeifer GP (ed), Plenum Press, New York, pp. 45-61, 1996.
17. Gupta RC, Arif JM. Chem. Res. Toxicol. 2001; 14: 951-957.
18. Arif JM, Gupta RC. Int. J. Oncol. 2003; 10:2071-2074.
19. Abrahams PJ, Houweling A, Cornelissen-Steijger PDM, Jaspers NGJ, Darroudi F, Meijers CM et al. Mut Res. 1998; 407: 189-201.
20. Hannan MA, Siddiqui Y, Rostom A, Al-Ahdal MN, Chaudhary MA, Kunhi M. Cancer Res. 2001; 61: 3627-3631.
21. Smith WA, Gupta RC. Carcinogenesis 1996; 17: 1285-1290.
22. Smith WA, Arif JM, Gupta RC. Mut. Res. 1998; 412: 307-314.
23. Smith WA, Freeman JW, Gupta RC. Mut. Res. 2001; 480-481:97-108.
24. Arif JM, Gairola CG, Glauert HP, Lubet RA, Kelloff GJ, Gupta RC. Carcinogenesis 1998; 19: 1515-1517.
25. Arif JM, Gairola CG, Kelloff GJ, Lubet RA, Gupta RC. Mut. Res. 2000; 452: 11-18.
26. Smith WA, Arif JM, Gupta RC. Int. J. Cancer 2001; 91:132-136.
27. Arif JM, Gupta RC. Int. J. Oncol. 1996; 8: 681-685.
28. Liggett WH Jr, Sidransky D. J Clin. Oncol. 1998; 16:1197-1206.
29. Levine A J. Cell 1997; 88: 323-331.
30. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW. Am. J. Pathol. 1999; 154:313-323.
31. Tsihlias J, Kapusta L, Slingerland J. An. Rev. Med. 1999; 50:401-423.
32. Greenwald P, Kelloff GJ, Boone CW, McDonald SS. Cancer Epidemiol. Biomarkers Prev. 1995; 4: 691-702.